A NEW AND HIGHLY SENSITIVE METHOD FOR MEASURING 3-METHOXYTYRAMINE USING HPLC WITH ELECTROCHEMICAL DETECTION - STUDIES WITH DRUGS WHICH ALTER DOPAMINE METABOLISM IN THE BRAIN

被引:31
作者
HEAL, DJ
FRANKLAND, ATJ
BUCKETT, WR
机构
[1] Boots Pharmaceuticals Research Department, Nottingham
关键词
3-methoxytyramine; high performance liquid chromatography (HPLC); dopamine; rat; brain; drug effects;
D O I
10.1016/0028-3908(90)90038-S
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
3-Methoxytyramine (3-MT) is a minor metabolite of dopamine which is suggested to reflect the turnover and utilization of dopamine. A novel, isocratic HPLC method has been developed which can be used to analyse 3-MT in homogenates of rat brain without the need for additional purification procedures. Furthermore, the coulometric electrochemical detection system is sensitive enough to measure 3 pg of 3-MT (equivalent to 0.6 ng/g tissue wet weight). 3-Methoxytyramine was measured in the striatum and n. accumbens after decapitation and rapid freezing, using 3-methoxy-4-hydroxybenzylamine as the internal standard. The effects of dopaminergic and other drugs on this metabolite were examined using this method. α-Methyl-p-tyrosine (200 mg/kg i.v.) produced parallel linear decreases in dopamine and 3-MT in naive rats, but not those pretreated with tranylcypromine (5 mg/kg i.p.). Methamphetamine (0.3-10 mg/kg i.p.) and amphetamine (0.3-10 mg/kg i.p.) both dose-dependently increased 3-MT in naive and tranylcypromine-pretreated rats. In naive animals, 3-MT was not altered by intraperitoneal injection of the dopamine reuptake inhibitors, bupropion (10 mg/kg) and nomifensine (10 mg/kg) or by sibutramine HCl (3 mg/kg), amitriptyline (10 mg/kg), desipramine (10 mg/kg) and zimeldine (10 mg/kg). 3-Methoxy-tyramine was decreased by apomorphine (5 mg/kg i.p.) and also by large doses of the selective D2 antagonist, BRL 34778 (5 mg/kg i.p.) or l-DOPA (50 mg/kg i.p.). The selective D1 antagonist, SCH 23390 (0.1 or 5 mg/kg i.p.) was without effect. In tranylcypromine-pretreated rats, 3-MT was dose-dependently reduced and increased by apomorphine (0.01-5 mg/kg i.p.) and BRL 34778 (0.1-5 mg/kg i.p.), respectively. The drug SCH 23390 (0.1-5 mg/kg i.p.) produced much smaller increases in 3-MT which were probably mediated through the striatonigral pathway. Overall, the data suggest that measurement of 3-MT, after inhibition of monoamine oxidase, is a useful index of the release and utilization of dopamine. However, after substantial and prolonged depletion of dopamine, levels of 3-MT in naive animals are a better index. Also, the formation of 3-MT in naive rats provides a sensitive method for distinguishing between dopamine releasing agents and reuptake inhibitors. © 1990.
引用
收藏
页码:1141 / 1150
页数:10
相关论文
共 41 条
[1]   APPLICATION OF THE DUAL-CELL COULOMETRIC DETECTOR - A METHOD FOR ASSAYING MONOAMINES AND THEIR METABOLITES [J].
ACHILLI, G ;
PEREGO, C ;
PONZIO, F .
ANALYTICAL BIOCHEMISTRY, 1985, 148 (01) :1-9
[2]   MONOAMINE-OXIDASE AND ALDEHYDE DEHYDROGENASE-ACTIVITY IN STRIATUM OF RATS AFTER 6-HYDROXYDOPAMINE LESION OF NIGROSTRIATAL PATHWAY [J].
AGID, Y ;
JAVOY, F ;
YOUDIM, MBH .
BRITISH JOURNAL OF PHARMACOLOGY, 1973, 48 (01) :175-178
[3]  
ALTAR CA, 1987, J PHARMACOL EXP THER, V242, P115
[4]   CGS-10746B - AN ATYPICAL ANTIPSYCHOTIC CANDIDATE THAT SELECTIVELY DECREASES DOPAMINE RELEASE AT BEHAVIORALLY EFFECTIVE DOSES [J].
ALTAR, CA ;
WASLEY, AM ;
LIEBMAN, J ;
GERHARDT, S ;
KIM, H ;
WELCH, JJ ;
WOOD, PL .
LIFE SCIENCES, 1986, 39 (08) :699-705
[5]   MODULATION OF INVIVO DOPAMINE RELEASE BY D-2 BUT NOT D-1 RECEPTOR AGONISTS AND ANTAGONISTS [J].
BOYAR, WC ;
ALTAR, CA .
JOURNAL OF NEUROCHEMISTRY, 1987, 48 (03) :824-831
[6]  
BROWN F, 1988, PSYCHOPHARMACOLOGY, V94, P350
[7]   POSTMORTAL ACCUMULATION OF 3-METHOXYTYRAMINE IN BRAIN [J].
CARLSSON, A ;
LINDQVIS.M ;
KEHR, W .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1974, 284 (04) :365-372
[8]  
COSTA E, 1966, BIOCHEMISTRY PHARMAC, P141
[9]  
COSTA E, 1970, BIOCH PSYCHOPHARMAC, V2, P160
[10]   MEASUREMENT OF 3-METHOXYTYRAMINE BY INVIVO VOLTAMMETRY - EVIDENCE FOR DIFFERENCES IN CENTRAL DOPAMINE FUNCTION IN BALB/C AND CBA MICE [J].
CRESPI, F ;
MARTIN, KF ;
HEAL, DJ ;
MARSDEN, CA ;
BUCKETT, WR ;
SANGHERA, MK .
BRAIN RESEARCH, 1989, 500 (1-2) :241-246